Cercare Medical is pleased to announce our presence at the 19th Meeting of the European Association of Neuro-Oncology (EANO 2024), taking place from October 17-20, 2024, in Glasgow, United Kingdom. As Europe’s largest neuro-oncology congress, EANO 2024 provides the ideal platform for us to demonstrate our commitment to advancing technology in the neuro-oncology field.
Being part of this congress is significant for us, as it aligns with our mission to support ongoing clinical and technological progress in the understanding and management of neuro conditions. At Cercare Medical, we demonstrate our dedication to this goal by introducing our groundbreaking Metabolic Perfusion Imaging technology. This innovative solution goes beyond traditional imaging by providing high-resolution maps of microvascular flow, offering clinicians unprecedented insights into brain metabolism and tissue health.
Visit our booth to experience live demonstrations of our cutting-edge perfusion imaging technologies. Discover how our software solutions enhance diagnostic precision and streamline clinical decision-making processes across a range of neurological conditions.
- Onsite Demo: Opportunity to engage with our technology and explore its real-world applications.
- Meet our Team: Our team will be available to discuss how Cercare Medical’s innovative solutions can be smoothly incorporated into your clinical workflows.
At EANO 2024, we look forward to showcasing how Cercare Medical’s solutions are paving the way by advancing the capabilities of perfusion imaging. Our goal is to empower healthcare professionals with the tools they need to enhance diagnostic accuracy in the neuro field.
Cercare Medical is a provider of advanced perfusion imaging solutions. With fully automated and multi-vendor compatible software for CT and MRI perfusion imaging post-processing, we are committed to delivering cutting-edge technology that enhances patient care and advances medical diagnostics across various neurological conditions, including Stroke, Oncology, Alzheimer's, Dementia, and COVID-19. Our proprietary biomarkers allow for better, more precise imaging maps, improving decision-making in critical care and enhancing neuroimaging. This innovative technology has led to widespread adoption by leading hospitals and clinics around the world.
